PARK7/DJ-1 in microglia: implications in Parkinson's disease and relevance as a therapeutic target

Frida Lind-Holm Mogensen1,2, Andrea Scafidi1,2, Aurélie Poli1

  • 1Neuro-Immunology Group, Department of Cancer Research, Luxembourg Institute of Health, 6A Rue Nicolas-Ernest Barblé, L-1210, Luxembourg, Luxembourg.

Insights

DJ-1 protein deficiency is linked to Parkinson's disease (PD) pathogenesis by affecting microglia. Targeting DJ-1 pathways in microglia offers potential therapeutic strategies for PD.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Microglia are brain immune cells crucial for surveillance and protection.
  • In neurodegenerative diseases like Parkinson's disease (PD), microglia can promote harmful inflammation.
  • Genetic mutations, accounting for 10% of PD cases, illuminate disease mechanisms.

Purpose of the Study:

  • To review the role of DJ-1 protein in neuroinflammation, specifically in microglia.
  • To explore DJ-1's function in microglial genetic programs and immune responses.
  • To discuss therapeutic strategies targeting DJ-1-related pathways in PD.

Main Methods:

  • Literature review focusing on DJ-1, microglia, and Parkinson's disease.
  • Analysis of DJ-1's role in oxidative stress and neuroinflammation.
  • Examination of genetic programs and immunological traits in microglia.

Main Results:

  • DJ-1 deficiency, caused by PARK7 mutations, leads to early-onset PD.
  • DJ-1's primary role involves protection against oxidative stress, but its link to PD onset is under investigation.
  • Dysregulated microglial pathways in DJ-1 deficiency are relevant to PD pathogenesis.

Conclusions:

  • DJ-1 plays a critical role in regulating microglial functions and neuroinflammation in PD.
  • Targeting DJ-1-modulated pathways in microglia presents a promising therapeutic avenue for PD.
  • Oxidized DJ-1 may serve as a biomarker for PD, and DJ-1 enhancers could be therapeutic agents.